RevoLix120瓦二微米激光前列腺汽化剜除术治疗高危良性前列腺增生  

The RevoLix 120 W 2 microm continuous-wave laser vaporesection of the prostate for the treatment of high-risk patients with benign prostatic hyperplasia

作　　者：王毓斌[1] 邵晋凯[1] 吕永安[1] 李晓东[1] 

机构地区：[1]山西省人民医院泌尿外科,太原030012

出　　处：《中国医师进修杂志》2011年第35期1-3,共3页Chinese Journal of Postgraduates of Medicine

基　　金：基金项目：山西省人民医院青年科研基金（2010-049）

摘　　要：目的探讨RevoLix120W2μm激光前列腺汽化剜除术治疗高危良性前列腺增生（BPH）的安全性和有效性。方法2010年1—12月，采用经尿道RevoLix120W2μm激光前列腺汽化剜除术治疗高危BPH患者62例。观察手术时间、血红蛋白和血清钠变化、留置导尿管时间、手术并发症、国际前列腺症状评分（IPSS）、生活质量（QOL）评分、残余尿（PVR）、最大尿流率（Qmax）等指标。结果手术均顺利完成。手术时间（52．6±28．2）min，无输血病例，术后均无心、脑、肝、肾等系统性疾病加重。术后留置导尿管时间3～6d。手术前后血红蛋白分别为（132±26）玑和（128±21）g／L，血清钠分别为（142．4±4．9）mmol／L和（141．2±3．8）mmol／L，差异无统计学意义（P〉0．05）。62例患者术后随访（7．2±3．5）个月，术后Qmax由术前的（7．6±4．2）ml／s增至（21．8±5．9）ml／s，PVR由术前的（124．4±206．2）ml降至（21．5±26．5）ml，IPSS及QOL评分分别由术前的（20．4±6．8）、（4．5±0．9）分降至（6．2±2．2）、（2．0±0．3）分，差异有统计学意义（P〈0．01）。结论RevoLix120W2μm激光前列腺汽化剜除术治疗高危BPH安全有效，但应掌握手术技巧和加强围手术期处理。Objective To evaluate the safety and efficacy of the RevoLix 120 W 2 microm continuous-wave laser vaporesection of the prostate for the treatment of high-risk patients with benign prostatic hyperplasia（BPH）. Methods From January to December 2010,62 high-risk patients with BPH underwent 2 microm continuous-wave laser vaporesection of the prostate. The operative time,decreased index in hemoglobin, decreased index in serum sodium,indwelling catheterization time,operative complications, international prostatic symptom scores （IPSS）,quality oflife（QOL） scores,peak urinary flow rate （Qmax）,and post voiding residual urine volume （PVR） were observed. Results All 62 patients recovered without incidents. Transfusions were not necessary in any patients. The operative time was （52.6 ± 28.2） min. The diseases of heart, brain, liver, kidnty were not worsen after operation. The indwelling catheterization time was 3-6 days. Hemoglobin decreased from preoperative （ 132 ± 26） g/L to postoperative （ 128 ± 21 ） g/L, serum sodium decreased from preoperative （ 142.4 ± 4.9） mmol/L to postoperative （ 141.2 ± 3.8 ） mmol/L. There were not significantly different between preoperative and postoperative results （P 〉 0.05）. All cases were followed up for （7.2 ±3.5） months, Qmax increased from （7.6 ±4.2） ml/s to （21.8±5.9） ml/s, PVR decreased from （124.4 ± 206.2 ） ml to （21.5 ± 26.5） ml. IPSS and QOL scores decreased from preoperative （20.4 ±6.8） and （4.5 ±0.9） scores to postoperative （6.2 ±2.2） and （2.0 ±0.3） scores. There were signifieantly different between preoperative and postoperative results（P 〈 0.01 ）. Conclusions The RevoLix 120 W 2 mierom continuous-wave laser vaporeseetion of the prostate is safe and effeetive for the treatment of high-risk patients with BPH. But should improve surgical techniques in the operative procedure and strengthen individual perioperative management.

关 键 词：前列腺增生 前列腺切除术 2微米激光 120 W REVOLIX 

分 类 号：R697.32[医药卫生—泌尿科学]